LOGIN  |  REGISTER
Assertio

Cytokinetics (NASDAQ: CYTK) Stock Quote

Last Trade: US$70.11 -1.30 -1.82
Volume: 1,574,263
5-Day Change: 4.08%
YTD Change: -16.03%
Market Cap: US$7.220B

Latest News From Cytokinetics

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73 rd Annual Scientific Session (ACC.24) taking place in Atlanta, GA from April 6, 2024 – April 8, 2024. Title: 1075-11 - Efficacy and Safety of Aficamten in the First Cohort of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy... Read More
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, Andrew Callos, Executive Vice President and Chief Commercial Officer, and Fady I. Malik, Executive Vice President of... Read More
SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate of 28,500 shares of common stock to three new employees, whose employment commenced in February 2024, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $72.24 per... Read More
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day®. Rare Disease Day® is an international campaign elevating the awareness and public understanding of rare diseases. The initiative spotlights the... Read More
SOUTH SAN FRANCISCO, Calif., and ALBANY, Ga., and WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), together with The Mended Hearts, Inc. and WomenHeart: The National Coalition for Women with Heart Disease, today announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials, an initiative designed to champion greater awareness and engagement in cardiovascular clinical... Read More
Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit New Drug Application for Aficamten to FDA in Q3 2024 and Marketing Authorization Application to EMA in Q4 2024 Primary Results from SEQUOIA-HCM Are Expected to be Presented at an Upcoming Medical Conference... Read More
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 27, 2024 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More
SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024 at 10:40 AM Eastern Time. Interested parties may access the live webcast of the fireside chat... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its sixth annual Communications Grant Program, intended to support increased capacity in communications, awareness building and community engagement. Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations focused on the hypertrophic... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function and fibrosis related to treatment with aficamten in FOREST-HCM ( F ollow-up, O pen-Label, R esearch E valuation of S ustained T reatment with Aficamten in HCM ), the open label extension clinical trial of aficamten in... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced an upcoming presentation at CMR 2024 taking place online and in person in London, UK from January 25-27, 2024. Title: Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy: The FOREST-HCM CMR Sub-study Presenter: Ahmad Masri, M.D., MS, Director of the... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 29, 2023 it granted stock options to purchase an aggregate of 6,150 shares of common stock to three new employees, whose employment commenced in December 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $83.49 per... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 7:30 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA. Interested parties may access the live... Read More
Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant and Clinically Meaningful Improvements in All Secondary Endpoints No Instances of Treatment Interruptions Due to Low LVEF Company to Host Conference Call and Webcast Today at 8:30 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif.,... Read More
SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM Eastern Time on Wednesday, December 27, 2023 to discuss the topline results from SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), the pivotal Phase 3 clinical trial... Read More
As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints Trial Discontinued in March 2023 Due to Futility Following Second Planned Interim Analysis Survey Reveals Site Personnel and Patients Have Favorable View of Trial Features to Reduce Burden of Participation SOUTH SAN FRANCISCO, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics,... Read More
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate of 25,350 shares of common stock to two new employees, whose employment commenced in November 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.48 per... Read More
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34 th International Symposium on ALS/MND taking place in Basel, Switzerland and online from December 6, 2023 - December 8, 2023. Oral Presentations Title : Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALS Presenter : Stacy... Read More
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2023 it granted stock options to purchase an aggregate of 22,350 shares of common stock to five new employees, whose employment commenced in October 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $34.86 per... Read More
On Track for Topline Results from SEQUOIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM, in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Initiated Enrollment in ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM... Read More
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in November: UBS BioPharma Conference on Wednesday, November 8, 2023 at 1:00 PM Eastern Time in a fireside chat with Fady I. Malik, Executive Vice President of Research & Development, and Andrew Callos, Executive Vice... Read More
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 2, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten, Show Sustained Improvements in Clinical Efficacy Endpoints and No Treatment Interruptions for Low Ejection Fraction Commercial Readiness Activities Leverage Insights from Market Research to Inform Market Segmentation and Patient-Centric Strategies New Pre-Clinical Data for CK-586 Shows Improved Diastolic Function and Reduced Cardiac Fibrosis in... Read More
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the baseline characteristics of patients randomized in SEQUOIA-HCM ( S afety, E fficacy, and Q uantitative U nderstanding of O bstruction I mpact of A ficamten in HCM ), the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), were... Read More
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host a virtual Investor and Analyst Day on Thursday, October 19, 2023 from 8:30 AM to 11:30 AM ET. The event, entitled New Horizons in Hypercontractility, will feature presentations from senior leaders about the Company’s cardiac myosin inhibition programs in hypertrophic cardiomyopathy (HCM)... Read More
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 29, 2023 it granted stock options to purchase an aggregate of 5,700 shares of common stock to two new employees, whose employment commenced in September 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $29.46 per... Read More
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced upcoming presentations at the 2023 Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions on October 6, 2023, and at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, taking place from October 6-9, 2023, both taking place in Cleveland, OH. 2023 HCMS Scientific Sessions... Read More
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases Deadline for Applications is November 1 st , 2023 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced a call for proposals for the sixth annual Cytokinetics Communications Grant Program. The program... Read More
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in September: Morgan Stanley 21 st Annual Global Healthcare Conference on Monday, September 11, 2023 at 8:00 AM Eastern Time in a fireside chat with Robert I. Blum, President and Chief Executive Officer, and Fady I. Malik,... Read More
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM ( A ssessment C omparing A ficamten to Placebo on C ardiac Endpoints I n A dults with Non-Obstructive HCM ), a Phase 3 clinical trial of aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), is open to enrollment. Aficamten is a next-in-class cardiac... Read More
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2023 it granted stock options to purchase an aggregate of 77,800 shares of common stock to 4 new employees, whose employment commenced in August 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $34.94 per share,... Read More
Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year Initiated Enrollment in MAPLE-HCM, a Phase 3 Clinical Trial Comparing Aficamten and Metoprolol in Obstructive HCM ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM, Expected to Start in September 2023 Company Reduces Projected Spending by Approximately... Read More
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 31, 2023 it granted stock options to purchase an aggregate of 60,200 shares of common stock to 3 new employees, whose employment commenced in July 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $33.35 per share, which... Read More
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 3, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on June 30, 2023 it granted stock options to purchase an aggregate of 77,450 shares of common stock to 5 new employees, whose employment commenced in June 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $32.62 per share, which... Read More
First Phase 3 Trial Evaluating Monotherapy with a Cardiac Myosin Inhibitor Compared to Monotherapy with a Beta Blocker in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MAPLE-HCM ( M etoprolol vs A ficamten in P atients with L VOT Obstruction on E xercise Capacity in HCM) , a Phase 3... Read More
SOUTH SAN FRANCISCO, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2023 it granted stock options to purchase an aggregate of 76,800 shares of common stock to 7 new employees, whose employment commenced in May 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $37.69 per share, which... Read More
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Jefferies Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside chat on Thursday, June 8, 2023... Read More
HealthStocksHub
Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical Trial in Non-Obstructive HCM To Begin in 2H 2023 SOUTH SAN FRANCISCO, May 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated... Read More
SOUTH SAN FRANCISCO, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced one Late Breaking Clinical Trial presentation and two moderated ePoster presentations at Heart Failure 2023 an International Congress of the European Society of Cardiology taking place online and in Prague, Czech Republic from May 20, 2023 – May 23, 2023. Late Breaking Clinical Trial Title:... Read More
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose clinical study of CK-4021586 (CK-586). CK-586 is a cardiac myosin inhibitor in development for the potential treatment of patients with heart failure with... Read More
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the JMP Securities Life Sciences Conference on Monday, May 15, 2023 at 9:00 AM Eastern Time at the New York Hilton Midtown in New York, NY. Interested parties may access the live webcast of this... Read More
SEQUOIA-HCM Nearing Completion of Enrollment; On Track for Results in Q4 2023 Additional Data from Cohort 4 of REDWOOD-HCM to be Presented in Late-Breaking Clinical Trial Session at European Society of Cardiology Heart Failure 2023 Congress Company to Reduce Spending by More Than 10% in 2023 to Maintain Over 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated... Read More
SOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 10, 2023 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA. Immediately after the conclusion of the Annual Meeting of Stockholders, Robert I. Blum, President and Chief Executive... Read More
SOUTH SAN FRANCISCO, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on April 28, 2023 it granted stock options to purchase an aggregate of 97,550 shares of common stock to 5 new employees, whose employment commenced in April 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $37.40 per share,... Read More
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The conference... Read More
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2023 at 10:00 AM Eastern Time. Interested parties may access the live webcast of this fireside chat by visiting the... Read More
SOUTH SAN FRANCISCO, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2023 it granted stock options to purchase an aggregate of 57,600 shares of common stock to 4 new employees, whose employment commenced in March 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $35.19 per share,... Read More
Company Plans to Discontinue the Phase 3 Clinical Trial of Reldesemtiv After Data Monitoring Committee Found No Effect on Primary or Key Secondary Endpoints Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Data Monitoring Committee (DMC) for COURAGE-ALS ( C linical O... Read More
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report , outlining the Company's commitment to social and environmental responsibility, ethics and governance and patient and community engagement. “At Cytokinetics, being a responsible corporate citizen is a natural extension of our company values,... Read More
SOUTH SAN FRANCISCO, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences: Oppenheimer 33 rd Annual Healthcare Conference: Robert I. Blum, President and Chief Executive Officer, will present virtually on Monday, March 13, 2023 at 10:00 AM Eastern Time. Barclays Global Healthcare Conference:... Read More
Treatment with Aficamten Resulted in Significant Improvements in Heart Failure Symptoms and Cardiac Biomarkers in Patients with Non-Obstructive HCM, Supporting Advancement to Phase 3 Additional Results from FOREST-HCM Demonstrate Long-Term Treatment with Aficamten for 48 Weeks is Well-Tolerated and Associated with Sustained Treatment Effect Company to Host Investor Event and Conference Call on March 6, 2023 at 8:30 AM... Read More
SOUTH SAN FRANCISCO, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2023 it granted stock options to purchase an aggregate of 21,450 shares of common stock to 5 new employees, whose employment commenced in February 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $43.36 per... Read More
Company Received Complete Response Letter from FDA for New Drug Application for Omecamtiv Mecarbil Data from Cohort 4 of REDWOOD-HCM to be Presented at the American College of Cardiology Scientific Sessions; Results Expected from SEQUOIA-HCM in Q4 2023 Second Interim Analysis of COURAGE-ALS Expected to Occur in Q2 2023 Company Provides 2023 Financial Guidance; More than 2 Years of Cash Runway SOUTH SAN FRANCISCO, Calif.,... Read More
Complete Response Letter States that GALACTIC-HF Alone Does not Establish Substantial Evidence of Effectiveness Sufficient for Approval Company Expects to Request Meeting with FDA to Discuss Potential Next Steps Cytokinetics to Host Conference Call and Webcast on March 1, 2023 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that... Read More
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the American College of Cardiology 72 nd Annual Scientific Session (ACC.23) taking place in New Orleans, LA from March 4, 2023 – March 6, 2023. Title: 1560-153 - Aficamten in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)... Read More
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and the National Organization for Rare Disorders (NORD) to recognize Rare Disease Day® on February 28, 2023. Rare Disease Day® is an international campaign elevating the awareness and public understanding of rare diseases. The... Read More
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 1, 2023 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss operational and financial results and the company’s outlook for the future. The... Read More
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $42.48 per... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its fifth annual Communications Grant Program, intended to support communications, awareness building and community engagement for nonprofit organizations serving the patient community. Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 30, 2022 it granted stock options to purchase an aggregate of 130,000 shares of common stock to 6 new employees, whose employment commenced in December 2022, as a material inducement to their employment. The stock options that were granted are subject to an exercise price of $45.82 per... Read More
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:00 AM Pacific Time at the Westin St. Francis Hotel in San Francisco. Interested parties may access the live webcast of this presentation... Read More
PDUFA Target Action Date is February 28, 2023 Cytokinetics to Host Conference Call and Webcast on December 14, 2022 at 8:30 am Eastern Time SOUTH SAN FRANCISCO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted 8 to 3 that the benefits of omecamtiv mecarbil do not... Read More
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) posted briefing documents for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC) meeting to review the New Drug Application (NDA) for omecamtiv mecarbil, an investigational selective, small molecule cardiac myosin activator for the treatment of... Read More
Advancement of Novel Cardiac Troponin Activator Expands Cardiovascular Franchise for Conditions Associated with Impaired Cardiac Contractility SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of... Read More
Assertio

COPYRIGHT ©2023 HEALTH STOCKS HUB